Severe Hypertriglyceridemia Market Set for Growth During the Forecast Period (2026-2036) Following Approval of Ionis' TRYNGOLZA and Emergence of Novel Therapies | DelveInsight

The report estimates nearly 3.64 million diagnosed severe hypertriglyceridemia cases across the seven major markets in 2025, with cases and treatment-market size expected to grow through 2036; the United States was the largest market in 2025. Ionis received FDA approval in June 2026 for Tryngolza (olezarsen) to lower triglycerides and reduce acute-pancreatitis risk in adults with the condition, while candidates from Arrowhead, 89bio, Lilly, Ionis and others remain in development. The outlook is positive for market expansion, although the release provides no market-size dollar estimate and notes substantial unmet treatment need.

Analysis

The commercial question is not the size of the epidemiology forecast but how quickly newly treated patients can be identified, reimbursed and retained on therapy. A large diagnosed pool does not automatically translate into drug sales: the reported treatment gap may reflect diagnostic friction, affordability or limited perceived benefit, all of which can slow uptake even after regulatory approval. The market-research release supplies no independent launch, pricing, payer-access or persistence data, so its growth framing is not an earnings thesis by itself.

Ionis has the clearest near-term commercial proof point among the mapped companies; successful uptake could improve investor confidence in its ability to commercialize beyond rare-disease markets. But first-mover status is vulnerable: plozasiran and other candidates could compete on efficacy, dosing burden, safety and access, while competing modalities may pressure net pricing before the patient pool is fully developed. This creates a potential second-order benefit for payers and a risk to incumbent triglyceride-lowering products, including Amarin’s VASCEPA, though SHTG exposure alone does not establish a material threat to Amarin’s consolidated economics. Arrowhead is a catalyst-driven opportunity, not yet a launch-equivalent story; verify the regulatory filing and trial-to-label path. Eli Lilly’s candidate is strategically relevant but the article provides no basis to underwrite a meaningful contribution to LLY.

Over the next 1–3 months, prioritize verified prescription, coverage and access signals over prevalence forecasts. Over 6–18 months, watch competitor data and payer response for evidence of share capture versus category expansion. The contrarian risk is that consensus extrapolates a large unmet need into rapid penetration; the thesis improves only if real-world use and reimbursement confirm conversion. Falsifiers include weak launch uptake, restrictive coverage, safety/tolerability issues, or competitor results that narrow differentiation.

Key Decisions for Investors

• No immediate trade on the DelveInsight release alone. Treat it as a watchlist catalyst; it contains no independent evidence of commercial uptake, net pricing or reimbursement.
• For IONS, consider a staged long only after verifying launch prescriptions, payer coverage and persistence. Reassess if uptake is weak or access remains restrictive; do not value the broader market forecast as realized revenue.
• Keep ARWR event-driven: verify the anticipated sNDA filing and regulatory timing, then reassess against the pivotal dataset and proposed label. Do not treat the filing expectation as approval certainty.
• Avoid an outright AMRN short based solely on SHTG competition. If later data show meaningful displacement of VASCEPA in this indication, assess a small, beta-aware IONS/AMRN relative-value position only after establishing the indication’s share of Amarin’s economics and the new product’s access profile.